Aliases & Classifications for Paronychia

MalaCards integrated aliases for Paronychia:

Name: Paronychia 12 76 29 55 44 15
Paronychia Inflammation 12 73
Onychia and Paronychia of Finger 12
Onychia and Paronychia of Toe 12
Fungal Nail Infection 12
Infected Nailfold 12
Onychomycosis 73

Classifications:



External Ids:

Disease Ontology 12 DOID:13117
ICD10 33 L03.0
MeSH 44 D010304
NCIt 50 C79702
SNOMED-CT 68 71906005

Summaries for Paronychia

Disease Ontology : 12 A nail disease characterized by often-tender bacterial or fungal hand infection or foot infection due to either bacteria or fungus (Candida albicans) where the nail and skin meet at the side or the base of a finger or toe nail. The infection can start suddenly (acute paronychia) or gradually (chronic paronychia). Puss is usually present, along with gradual thickening and browning discoloration of the nail plate.

MalaCards based summary : Paronychia, also known as paronychia inflammation, is related to aggressive digital papillary adenocarcinoma and adenocarcinoma. An important gene associated with Paronychia is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and HIV Life Cycle. The drugs Fluorouracil and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and colon, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Paronychia is a nail disease that is an often-tender bacterial or fungal infection of the hand or foot... more...

Related Diseases for Paronychia

Diseases related to Paronychia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 aggressive digital papillary adenocarcinoma 29.8 HRAS KRAS
2 adenocarcinoma 29.5 EGFR HRAS KRAS
3 candidal paronychia 12.1
4 neuropathy, hereditary sensory and autonomic, type iia 11.1
5 pemphigus 10.3
6 pyogenic granuloma 10.3
7 pemphigus vulgaris, familial 10.2
8 pemphigus vulgaris 10.2
9 leishmaniasis 10.2
10 cutaneous leishmaniasis 10.2
11 squamous cell carcinoma 10.1
12 dermatitis 10.1
13 luminal breast carcinoma 10.1 EGFR MTOR
14 geographic tongue 10.1 EGFR MTOR
15 contact dermatitis 10.1
16 sigmoid neoplasm 10.0 HRAS KRAS
17 apocrine adenoma 10.0 HRAS KRAS
18 periampullary adenoma 10.0 HRAS KRAS
19 schimmelpenning-feuerstein-mims syndrome 10.0 HRAS KRAS
20 bile duct cysts 10.0 HRAS KRAS
21 appendix disease 10.0 HRAS KRAS
22 lung adenoid cystic carcinoma 10.0 HRAS KRAS
23 nasal cavity adenocarcinoma 10.0 HRAS KRAS
24 secondary hypertrophic osteoarthropathy 10.0 HRAS KRAS
25 anal canal adenocarcinoma 10.0 HRAS KRAS
26 ovarian cystadenocarcinoma 10.0 HRAS KRAS
27 pulmonary blastoma 10.0 EGFR KRAS
28 estrogen-receptor positive breast cancer 10.0 EGFR MTOR
29 biliary papillomatosis 10.0 HRAS KRAS
30 colloid carcinoma of the pancreas 10.0 HRAS KRAS
31 core binding factor acute myeloid leukemia 10.0 HRAS KRAS
32 biliary tract neoplasm 10.0 HRAS KRAS
33 duodenum cancer 10.0 HRAS KRAS
34 liver angiosarcoma 10.0 HRAS KRAS
35 cecum adenocarcinoma 10.0 HRAS KRAS
36 costello syndrome 10.0 HRAS KRAS
37 ampulla of vater cancer 10.0 HRAS KRAS
38 mucinous adenocarcinoma 10.0 EGFR KRAS
39 gastrointestinal system benign neoplasm 10.0 HRAS KRAS
40 bile duct adenocarcinoma 10.0 HRAS KRAS
41 ovary adenocarcinoma 10.0 HRAS KRAS
42 intestinal benign neoplasm 10.0 HRAS KRAS
43 bronchiolo-alveolar adenocarcinoma 10.0 EGFR KRAS
44 pulmonic stenosis 10.0 HRAS KRAS
45 small intestine cancer 10.0 HRAS KRAS
46 malignant ovarian surface epithelial-stromal neoplasm 10.0 HRAS KRAS
47 ovary epithelial cancer 10.0 HRAS KRAS
48 nevus, epidermal 10.0 HRAS KRAS
49 neutropenia 10.0
50 osteomyelitis 10.0

Graphical network of the top 20 diseases related to Paronychia:



Diseases related to Paronychia

Symptoms & Phenotypes for Paronychia

GenomeRNAi Phenotypes related to Paronychia according to GeneCards Suite gene sharing:

26 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.73 EGFR MTOR HRAS KRAS
2 Decreased viability GR00106-A-0 10.73 KRAS
3 Decreased viability GR00221-A-1 10.73 EGFR MTOR HRAS KRAS MAP2K7
4 Decreased viability GR00221-A-2 10.73 HRAS KRAS
5 Decreased viability GR00221-A-3 10.73 WNK1 HRAS
6 Decreased viability GR00221-A-4 10.73 EGFR MTOR WNK1
7 Decreased viability GR00301-A 10.73 KRAS
8 Decreased viability GR00342-S-1 10.73 MTOR MAP2K7
9 Decreased viability GR00342-S-2 10.73 MTOR
10 Decreased viability GR00381-A-1 10.73 KRAS
11 Decreased viability GR00402-S-2 10.73 EGFR MTOR WNK1 HRAS KRAS MAP2K7
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.27 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.27 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.27 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.27 MTOR
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.27 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.27 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.27 KRAS
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.27 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.27 KRAS WNK1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.27 KRAS MTOR WNK1
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.27 MTOR
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.27 KRAS
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.27 WNK1
25 Decreased viability with paclitaxel GR00179-A-1 9.85 EGFR MTOR
26 Decreased viability with paclitaxel GR00179-A-2 9.85 MTOR
27 Decreased viability with paclitaxel GR00179-A-3 9.85 EGFR MTOR
28 Decreased substrate adherent cell growth GR00193-A-2 9.8 EGFR MAP2K7 MTOR WNK1
29 Decreased substrate adherent cell growth GR00193-A-3 9.8 MAP2K7 WNK1
30 Decreased cell migration GR00055-A-1 9.71 EGFR HRAS KRAS MTOR
31 Increased cell migration GR00055-A-3 9.26 EGFR HRAS KRAS MTOR
32 Reduced mammosphere formation GR00396-S 8.92 EGFR HRAS KRAS MTOR

MGI Mouse Phenotypes related to Paronychia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.88 EGFR HRAS KRAS MAP2K7 MTOR WNK1
2 cardiovascular system MP:0005385 9.85 EGFR HRAS KRAS MTOR WNK1
3 mortality/aging MP:0010768 9.85 EGFR HRAS KRAS MAP2K7 MTOR WNK1
4 endocrine/exocrine gland MP:0005379 9.83 EGFR HRAS KRAS MAP2K7 MTOR
5 nervous system MP:0003631 9.73 EGFR HRAS KRAS MAP2K7 MTOR WNK1
6 neoplasm MP:0002006 9.62 EGFR HRAS KRAS MAP2K7
7 no phenotypic analysis MP:0003012 9.46 EGFR HRAS KRAS MTOR
8 normal MP:0002873 9.35 EGFR HRAS KRAS MAP2K7 MTOR
9 renal/urinary system MP:0005367 9.02 EGFR HRAS KRAS MTOR WNK1

Drugs & Therapeutics for Paronychia

Drugs for Paronychia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 2 51-21-8 3385
2
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
3
Phytonadione Approved, Investigational Phase 4 84-80-0 4812 5284607
4
leucovorin Approved Phase 4,Phase 2 58-05-9 6006 143
5
Irinotecan Approved, Investigational Phase 4,Phase 2 100286-90-6, 97682-44-5 60838
6
Amorolfine Approved, Investigational Phase 4 78613-35-1
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
9
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
10 Mitogens Phase 4,Not Applicable
11 Vitamin B Complex Phase 4
12 Menaquinone Phase 4
13 Vitamin K Phase 4
14 Vitamins Phase 4
15 Vitamin B9 Phase 4
16 Antibodies Phase 4,Phase 2
17 Immunoglobulins Phase 4,Phase 2
18 naphthoquinone Phase 4
19 Vitamin K 1 Phase 4
20 Antibodies, Monoclonal Phase 4,Phase 2
21 Folate Phase 4
22 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
23 Antifungal Agents Phase 4
24
Petrolatum Approved, Investigational Phase 2 8009-03-8
25
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
26
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
27
Hydroxyzine Approved Phase 2 68-88-2 3658
28
Clindamycin Approved, Vet_approved Phase 2 18323-44-9 29029
29
Silver sulfadiazine Approved, Vet_approved Phase 2 22199-08-2 441244
30
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
31
Ciprofloxacin Approved, Investigational Phase 2 85721-33-1 2764
32
Amoxicillin Approved, Vet_approved Phase 2,Not Applicable 26787-78-0 33613
33
Sulfadiazine Approved, Investigational, Vet_approved Phase 2 68-35-9 5215
34
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
35
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
36
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
37
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
38
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
39
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
40 Lycopene Approved, Investigational Phase 2 502-65-8 446925
41 Tomato Approved Phase 2
42
Camptothecin Experimental Phase 2 7689-03-4
43
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
44 Pharmaceutical Solutions Phase 2
45 Cortisol succinate Phase 2
46 Anti-Bacterial Agents Phase 2,Not Applicable
47 Cola Phase 2
48 Antibiotics, Antitubercular Phase 2,Not Applicable
49 Emollients Phase 2,Not Applicable
50 Immunologic Factors Phase 2

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
2 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
3 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
4 Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Active, not recruiting NCT02514174 Phase 4 Afatinib
5 Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) Terminated NCT02695290 Phase 4 Afatinib
6 A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients Completed NCT03207906 Phase 2 VBP-926
7 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy Completed NCT00332163 Phase 2 Irinotecan;FOLFIRI;Pre-emptive Skin Treatment;Reactive Skin Treatment
8 Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Completed NCT01465802 Phase 2 Dacomitinib;Dacomitinib;Doxycycline;Probiotic;Alclometasone cream
9 A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer. Completed NCT00531934 Phase 2 Doxycline;erlotinib [Tarceva]
10 An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) Completed NCT00744757 Phase 2 Decitabine
11 Panitumumab Skin Toxicity Prevention Trial Recruiting NCT03167268 Phase 2 Lycopene
12 Impact of Antibiotic Treatment of Group A Streptococcal Blistering Distal Dactylitis in Children Completed NCT02624882 Not Applicable
13 GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations Completed NCT02047903 Afatinib
14 An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer Completed NCT01782690 erlotinib;gemcitabine
15 Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors Recruiting NCT03051880 Not Applicable Repair Control EGF®;Cream without rhEGF

Search NIH Clinical Center for Paronychia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: paronychia

Genetic Tests for Paronychia

Genetic tests related to Paronychia:

# Genetic test Affiliating Genes
1 Paronychia 29

Anatomical Context for Paronychia

MalaCards organs/tissues related to Paronychia:

41
Skin, Lung, Colon, Ovary, Pancreas, Myeloid, Small Intestine

Publications for Paronychia

Articles related to Paronychia:

(show top 50) (show all 233)
# Title Authors Year
1
Topical Betaxolol for Treating Relapsing Paronychia with Pyogenic Granuloma-Like Lesions Induced by Epidermal Growth Factor Receptor Inhibitors. ( 29339238 )
2018
2
Febrile neutropenia with bacterial paronychia. ( 29531738 )
2018
3
Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. ( 29894010 )
2018
4
Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine. ( 29117285 )
2018
5
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. ( 29902802 )
2018
6
Chronic Paronychia and Onychomadesis in Pemphigus Vegetans: An Unusual Presentation in a Rare Autoimmune Disease. ( 29560011 )
2018
7
Purulent Pericarditis Due to Paronychia in a 16-Month-Old Child: A Nail-Biting Story. ( 29506451 )
2018
8
Retronychia a little-known cause of paronychia: A report of two cases in adolescent patients. ( 29479729 )
2018
9
Systemic Drug-induced Chronic Paronychia and Periungual Pyogenic Granuloma. ( 30258794 )
2018
10
Papulopustules and paronychia in a lung carcinoma. ( 30297249 )
2018
11
Case series showing the efficacy of 5-aminolaevulinic acid photodynamic therapy for epidermal growth factor receptor inhibitor-induced paronychia and pyogenic granuloma-like lesions. ( 30298920 )
2018
12
Recurrent Paronychia as a Presenting Manifestation of Pemphigus Vulgaris: A Case Report. ( 28611998 )
2017
13
Acute and Chronic Paronychia. ( 28671378 )
2017
14
Nail Braces for Severe Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors: An alternative to nail extraction. ( 28987490 )
2017
15
Primary Cutaneous CD8+ T-cell Lymphoma, an Indolent and Locally Aggressive Form Mimicking Paronychia. ( 28984695 )
2017
16
Neonatal Acute Paronychia. ( 28720045 )
2017
17
Paronychia: What You Should Know. ( 28671380 )
2017
18
Chinese Medicine Treatment for Afatinib-Induced Paronychia. ( 28948057 )
2017
19
Paronychia with Sporangium Formation Causing an Ingrown Toenail A Rare Case Report. ( 29116824 )
2017
20
Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases. ( 28721095 )
2017
21
Pediatric Dermatology Photoquiz: Refractory Purulent Paronychia in a Young Girl. Paronychial cutaneous leishmaniasis. ( 26758096 )
2016
22
Acute felon and paronychia: Antibiotics not necessary after surgical treatment. Prospective study of 46 patients. ( 27117023 )
2016
23
Paronychia and granulation tissue formation during treatment with isotretinoin. ( 27192525 )
2016
24
Toenail paronychia. ( 27810017 )
2016
25
Non-healing ulcerative paronychia. ( 28017401 )
2016
26
sQuiz your knowledge: chronic paronychia of the third toe. ( 27241472 )
2016
27
Periungual Abscess Caused by Citrobacter braakii in a Patient with Chronic Paronychia. ( 27489449 )
2016
28
sQUIZ your knowledge: Chronic paronychia of the third toe. ( 27789424 )
2016
29
Paronychia and onychomadesis due to pemphigus vulgaris. ( 27506502 )
2016
30
Chronic paronychia treatment: Square flap technique. ( 26946988 )
2016
31
Paronychia-like digital metastases of osteosarcoma. ( 27495265 )
2016
32
Congenital Malalignment of the Great Toenails With Acute Paronychia. ( 27396767 )
2016
33
Ungual squamous cell carcinoma mimicking a chronic paronychia: clinical, pathological and radiological correlation. ( 26632936 )
2015
34
Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation. ( 26445556 )
2015
35
Evaluation of role of Candida in patients with chronic paronychia. ( 26087081 )
2015
36
HPLC-UV/DAD and ESI-MS(n) analysis of flavonoids and antioxidant activity of an Algerian medicinal plant: Paronychia argentea Lam. ( 25910047 )
2015
37
Tips to Treat the 5 Most Common Nail Disorders: Brittle Nails, Onycholysis, Paronychia, Psoriasis, Onychomycosis. ( 25828710 )
2015
38
Effective treatments for paronychia caused by oncology pharmacotherapy. ( 26596962 )
2015
39
Antibiotic Overuse and Paronychia: A Teachable Moment. ( 26569127 )
2015
40
Paronychia-like cutaneous leishmaniasis. ( 26632940 )
2015
41
Treatment and prevention of paronychia using a new combination of topicals: report of 30 cases. ( 25854670 )
2015
42
Case of Fusarium paronychia successfully treated with occlusive dressing of antifungal cream. ( 24533442 )
2014
43
Management of chronic paronychia. ( 24470654 )
2014
44
Oleanane type glycosides from Paronychia anatolica subsp. balansae. ( 24321579 )
2014
45
Images in clinical medicine. Cutaneous leishmaniasis with a paronychia-like lesion. ( 25354107 )
2014
46
Clinical and cytologic features of antibiotic-resistant acute paronychia. ( 24355264 )
2014
47
Periungual Bowen disease mimicking chronic paronychia and diagnosed by dermoscopy. ( 25128126 )
2014
48
Atypical chronic sterile paronychia leading to tissue and joint space destruction in a patient with thromboangiitis obliterans. ( 23127186 )
2014
49
Chronic paronychia in a hairdresser. ( 24985481 )
2014
50
Acute and chronic paronychia of the hand. ( 24603826 )
2014

Variations for Paronychia

Expression for Paronychia

Search GEO for disease gene expression data for Paronychia.

Pathways for Paronychia

Pathways related to Paronychia according to GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 EGFR HRAS KRAS MAP2K7 MTOR WNK1
2
Show member pathways
13.54 EGFR HRAS KRAS MAP2K7 MTOR
3
Show member pathways
13.51 EGFR HRAS KRAS MAP2K7 MTOR
4
Show member pathways
13.38 EGFR HRAS KRAS MAP2K7 MTOR
5
Show member pathways
13.27 EGFR HRAS KRAS MTOR WNK1
6
Show member pathways
13.15 EGFR HRAS KRAS MAP2K7
7
Show member pathways
13.06 EGFR HRAS KRAS MAP2K7 MTOR
8
Show member pathways
12.95 EGFR HRAS KRAS MTOR
9
Show member pathways
12.94 EGFR HRAS KRAS MTOR
10
Show member pathways
12.92 EGFR HRAS KRAS MAP2K7
11
Show member pathways
12.91 EGFR HRAS KRAS MAP2K7 MTOR
12
Show member pathways
12.89 EGFR HRAS KRAS MTOR
13
Show member pathways
12.82 EGFR HRAS KRAS MAP2K7 MTOR
14
Show member pathways
12.81 EGFR HRAS KRAS MTOR
15
Show member pathways
12.8 EGFR HRAS KRAS MAP2K7
16
Show member pathways
12.77 EGFR HRAS KRAS MTOR
17 12.74 EGFR HRAS KRAS MTOR
18
Show member pathways
12.71 HRAS KRAS MAP2K7 MTOR
19
Show member pathways
12.7 EGFR HRAS KRAS MAP2K7 MTOR
20 12.67 EGFR HRAS KRAS MAP2K7
21
Show member pathways
12.67 EGFR HRAS KRAS MTOR
22
Show member pathways
12.63 EGFR HRAS KRAS MTOR
23
Show member pathways
12.62 HRAS KRAS MAP2K7 MTOR
24
Show member pathways
12.6 EGFR HRAS KRAS
25
Show member pathways
12.6 EGFR HRAS KRAS
26
Show member pathways
12.59 EGFR HRAS KRAS MAP2K7
27
Show member pathways
12.56 EGFR HRAS KRAS MAP2K7 MTOR
28
Show member pathways
12.55 EGFR HRAS KRAS
29 12.52 EGFR HRAS KRAS
30
Show member pathways
12.49 EGFR HRAS KRAS
31
Show member pathways
12.48 HRAS KRAS MAP2K7
32 12.44 EGFR HRAS KRAS MTOR
33
Show member pathways
12.44 EGFR HRAS KRAS MAP2K7 MTOR
34
Show member pathways
12.43 HRAS MAP2K7 MTOR
35
Show member pathways
12.42 EGFR HRAS KRAS MTOR
36
Show member pathways
12.4 HRAS KRAS MTOR
37
Show member pathways
12.36 HRAS KRAS MAP2K7
38
Show member pathways
12.36 EGFR HRAS KRAS MTOR
39
Show member pathways
12.35 HRAS KRAS MAP2K7
40
Show member pathways
12.35 EGFR HRAS KRAS
41
Show member pathways
12.35 HRAS KRAS MAP2K7 MTOR
42
Show member pathways
12.34 EGFR HRAS KRAS
43
Show member pathways
12.34 EGFR HRAS KRAS MAP2K7
44
Show member pathways
12.33 EGFR HRAS KRAS MTOR
45
Show member pathways
12.31 EGFR HRAS KRAS MTOR
46
Show member pathways
12.29 HRAS KRAS MTOR
47
Show member pathways
12.27 HRAS KRAS MTOR
48
Show member pathways
12.26 HRAS KRAS MTOR
49
Show member pathways
12.25 EGFR HRAS KRAS
50
Show member pathways
12.25 EGFR HRAS KRAS MAP2K7 MTOR

GO Terms for Paronychia

Biological processes related to Paronychia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.73 HRAS KRAS MTOR
2 phosphorylation GO:0016310 9.67 EGFR MAP2K7 MTOR WNK1
3 MAPK cascade GO:0000165 9.63 EGFR HRAS KRAS
4 protein phosphorylation GO:0006468 9.62 EGFR MAP2K7 MTOR WNK1
5 Ras protein signal transduction GO:0007265 9.59 HRAS KRAS
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.58 HRAS KRAS
7 peptidyl-threonine phosphorylation GO:0018107 9.58 MTOR WNK1
8 positive regulation of epithelial cell proliferation GO:0050679 9.57 EGFR HRAS
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.55 EGFR MTOR
10 cellular response to amino acid stimulus GO:0071230 9.54 EGFR MTOR
11 negative regulation of GTPase activity GO:0034260 9.52 HRAS WNK1
12 visual learning GO:0008542 9.51 KRAS MTOR
13 cell aging GO:0007569 9.49 HRAS MTOR
14 positive regulation of DNA replication GO:0045740 9.48 EGFR HRAS
15 regulation of long-term neuronal synaptic plasticity GO:0048169 9.43 HRAS KRAS
16 protein autophosphorylation GO:0046777 9.43 EGFR MTOR WNK1
17 response to osmotic stress GO:0006970 9.4 EGFR MAP2K7
18 response to isolation stress GO:0035900 9.16 HRAS KRAS
19 positive regulation of MAP kinase activity GO:0043406 9.13 EGFR HRAS KRAS
20 positive regulation of protein phosphorylation GO:0001934 8.92 EGFR HRAS KRAS MTOR

Molecular functions related to Paronychia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.56 EGFR MAP2K7 MTOR WNK1
2 protein serine/threonine kinase activity GO:0004674 9.54 MAP2K7 MTOR WNK1
3 protein kinase activity GO:0004672 9.46 EGFR MAP2K7 MTOR WNK1
4 GDP binding GO:0019003 9.32 HRAS KRAS
5 protein kinase binding GO:0019901 9.26 EGFR MAP2K7 MTOR WNK1
6 nucleotide binding GO:0000166 8.92 EGFR HRAS KRAS MTOR

Sources for Paronychia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....